AstraZeneca receives accelerated FDA approval for rare disease treatment Ultomiris
AZN Astrazeneca plc
$172.57 +2.45%
View chart & analysis → - 1AstraZeneca's rare disease treatment Ultomiris (ravulizumab) has received accelerated approval from the US Food and Drug Administration for IgA nephropathy (IgAN).
- 2Ultomiris use in IgAN patients at week 34 showed a 43.4% reduction in excess urinary protein levels compared to placebo.
- 3Market competition is expected to intensify as Calliditas Therapeutics recorded $517 million in Tarpeyo sales in 2025.
So what's the key point?
AstraZeneca's rare disease treatment received fast-track approval in the US. Market competition will likely increase since a competing product generated $517 million in sales.
Source Pharmaceutical Technology +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.